nyuuzyou/wikis huggingface dataset:
Motesanib (AMG-706)

==Mechanism of action==
From the NCI Drug Dictionary: The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Thyroid cancer===
# Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. link to original article EuroPMC
==Also known as==
*Code name: AMG-706
Category:Drugs
Category:Oral medications
Category:VEGFR inhibitors
Category:PDGFR inhibitors
Category:KIT inhibitors
Category:RET inhibitors
Category:Thyroid cancer, differentiated medications (investigational)
Category:Halted drugs
Motixafortide (Aphexda)

==Mechanism of action==
cyclic-peptide CXCR4 inhibitor 
*IUPHAR/BPS
==History of changes in FDA indication==
*2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. (Based on GENESIS)
==Also known as==
*Code names: BKT-140, BL-8040, TF-14016
*Brand name: Aphexda
Category:Drugs
Category:Subcutaneous medications
Category:CXCR4 inhibitors
Category:Stem cell mobilization medications
Category:FDA approved in 2023
Category:Stub
Moxetumomab pasudotox (Lumoxiti)

==Mechanism of action==
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
==Diseases for which it is used==
*Hairy cell leukemia
==History of changes in FDA indication==
*2018-09-13: Initial approval for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). (Based on Study 1053)
==History of changes in EMA indication==
*2021-02-08: Initial authorization for treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies.
*2021-07-23: Authorization withdrawn at manufacturer request, for commercial reasons
==Also known as==
*Generic name: moxetumomab pasudotox-tdfk
*Code names: CAT-8015, HA22
*Brand name: Lumoxiti
Category:Drugs
Category:Intravenous medications
Category:Immunotoxin
Category:Anti-CD22 immunotoxins
Category:Hairy cell leukemia medications
Category:FDA approved in 2018
Category:EMA approved in 2021
Category:EMA withdrawn in 2021
Mycophenolate mofetil (CellCept)

==General information==
Class/mechanism: Immunosuppressive medication, inhibits inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil is converted in vivo to the active agent mycophenolic acid (MPA), which is a reversible, selective, and non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). MPA results in the inhibition of the de novo synthesis of guanosine, which T and B-cells are dependent upon for proliferation (as opposed to other cell types, which can use salvage pathways). MPA has a cytostatic effect on lymphocytes, suppresses antibody formation by B-cells, and inhibits T and B-cell proliferative response to mitogenic and allospecific stimuli. MPA also inhibits glycosylation of glycoproteins that play a role in intercellular adhesion to endothelial cells, which may suppress localization of leukocytes to areas of inflammation or graft rejection.Mycophenolate mofetil (CellCept) package insert Mycophenolate mofetil (CellCept) package insert (locally hosted backup)Cellcept manufacturer's website
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Toxicity management==
*Link to REMS program
==Disease for which it is used==
*Graft versus host disease
*Immune thrombocytopenia
==Patient drug information==
*Mycophenolate mofetil (CellCept) package insert
*Mycophenolate mofetil (CellCept) patient drug information (UpToDate)Mycophenolate mofetil (CellCept) patient drug information (UpToDate)
==History of changes in FDA indication==
*1995-05-03: Initial FDA approval
==History of changes in EMA indication==
*1996-02-14: Initial authorization
==History of changes in PMDA indication==
*2021-06-25: New indication and a new dosage for the suppression of graft-versus-host disease in hematopoietic stem cell transplantation.
==Also known as==
*Brand name: CellCept, Myclausen, Myfenex, Myhibbin
==References==
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:IMPDH inhibitors
Category:Graft versus host disease medications
Category:Immune thrombocytopenia medications
Category:REMS program
Category:FDA approved in 1995
Category:EMA approved in 1996
Myelodysplastic syndrome, IDH-mutated

Back to Top
Note: these are regimens tested in biomarker-specific populations for patients with IDH-mutated MDS, please see the main MDS page for other regimens.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Myelodysplastic Syndromes.
=IDH1 relapsed or refractory=
==Ivosidenib monotherapy==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment 	Evidence 	Efficacy
DiNardo et al. 2018 (AG120-C-001 r/r)	2014-03-12 to 2017-05-08	Phase 1/2 (RT)	ORR: 41.6%, 95% CI 32.9-50.8
====Biomarker eligibility criteria====
*Alteration: IDH1 mutation
====Targeted therapy====
*Ivosidenib (Tibsovo) 500 mg PO once per day on days 1 to 28
28-day cycles
===References===
#AG120-C-001 r/r: DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398. Epub 2018 Jun 2. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT02074839
Category:Myelodysplastic syndrome regimens
Category:Biomarker-specific pages
Category:Bone marrow failure syndromes
NET of unknown primary

Last updated on 2024-07-23:TBA regimens on this page
TBA variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ESMO==
*2015: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
==NCCN==
*NCCN Guidelines - Occult Primary (Cancer of Unknown Primary (CUP)
=All lines of therapy=
*Poorly differentiated or small cell tumors can be treated with small cell lung cancer regimens.
*Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for neuroendocrine tumors.
Category:NET of unknown primary regimens
Category:Site-agnostic regimens
Category:Malignant solid neoplasm
NK- and T-cell lymphoma - historical

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NKTCL page for current regimens.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
 
=Relapsed or refractory=
==Pembrolizumab monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Kwong et al. 2017	Not reported 	Case series
Note: prospective trials are underway.
====Immunotherapy====
*Pembrolizumab (Keytruda) 2 mg/kg IV once on day 1
21-day cycles
===References===
#Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article EuroPMC
Category:NK- and T-cell lymphoma regimens
Category:Historical regimens
Category:Disease-specific pages
Category:T-cell lymphomas
Nadofaragene firadenovec (Adstiladrin)

==General information==
From the NCI Drug Dictionary: A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.
==Diseases for which it is used==
*Bladder cancer
==History of changes in FDA indication==
*2022-12-16: Initial approval for adult patients with high-risk BCG vaccine unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on rAd-IFN-CS-003)
==Also known as==
*Code name: SCH-721015
*Generic name: nadofaragene firadenovec-vncg
*Brand name: Adstiladrin, Instiladrin
Category:Drugs
Category:Intravesical medications
Category:Immunotherapeutic
Category:Bladder cancer medications
Category:FDA approved in 2022
Nadroparin (Fraxiparine)

==General information==
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your pråeferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==History of changes in Health Canada indication==
*1997-11-27: Initial notice of compliance.
==Also known as==
*Brand names: Fraxiparine, Fraxodi
==References==
* Cancer-DACUS: Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, Mascheroni D, Bucherini E, Gallucci P, D'Alessio A, Prantera T, Spadaro P, Rotondo S, Di Micco P, Oriana V, Urbano O, Recchia F, Ghirarduzzi A, Lo Coco L, Mancuso S, Casuccio A, Rini GB, Siragusa S. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol. 2014 Nov 10;32(32):3607-12. Epub 2014 Sep 29. link to original article EuroPMC 
Category:Drugs
Category:Subcutaneous medications
Category:Anticoagulants
Category:Heparins
Category:Low molecular weight heparins
Category:Venous thromboembolism medications
Category:Health Canada approved in 1997
Naxitamab (Danyelza)

==General information==
Class/mechanism: glycolipid GD2 recombinant humanized monoclonal IgG1 antibody. Naxitamab-gqgk binds to the glycolipid GD2, which is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, binding resulted in complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).Naxitamab-gqgk (Danyelza) package insert Naxitamab-gqgk (Danyelza) package insert (locally hosted backup)Danyelza manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Neuroblastoma
==Patient drug information==
*Naxitamab-gqgk (Danyelza) package insert
==History of changes in FDA indication==
*2020-11-24: FDA accelerated approval to be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. (Based on Study 12-230 & Study 201)
==Also known as==
*Generic name: naxitamab-gqgk
*Brand name: Danyelza
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-GD2 antibodies
Category:Neuroblastoma medications
Category:FDA approved in 2020
Necitumumab (Portrazza)

==General information==
Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.Necitumumab (Portrazza) package insertNecitumumab (Portrazza) package insert (locally hosted backup)Portrazza manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Non-small cell lung cancer, squamous
==Patient drug information==
*Brief patient counseling information can be found in the Necitumumab (Portrazza) package insert
==History of changes in FDA indication==
*2015-11-24: FDA approved to be used in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. (Based on SQUIRE)
==History of changes in EMA indication==
*2016-02-15: Initial authorization for the treatment of squamous non-small cell lung cancer.
*2021-02-18: Authorization withdrawn at the request of the manufacturer, for commercial reasons
==History of changes in Health Canada indication==
*2017-03-16: Initial notice of compliance
==History of changes in PMDA indication==
*2019-06-18: Newly indicated for the treatment of unresectable advanced or recurrent squamous non-small cell lung cancer.
==Also known as==
*Code name: IMC-11F8
*Brand name: Portrazza
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-EGFR antibodies
Category:Non-small cell lung cancer, squamous medications
Category:FDA approved in 2015
Category:EMA approved in 2016
Category:EMA withdrawn in 2021
Category:Health Canada approved in 2017
Category:PMDA approved in 2019
Nedaplatin (Aqupla)

==General information==
Class/mechanism: A second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. NCI Drug Dictionary entry for nedaplatin
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Cervical cancer
*Nasopharyngeal carcinoma
*Non-small cell lung cancer, squamous
*Non-small cell lung cancer, EGFR-mutated
==Also known as==
*Code name: 254-S
*Generic name: nedaplat
*Brand name: Aqupla, Jiebaishu
==References==
Category:Drugs
Category:Intravenous medications
Category:Platinum agents
Category:Alkylating agents
Category:Cervical cancer medications
Category:Nasopharyngeal carcinoma medications
Category:Non-small cell lung cancer medications
Category:Non-small cell lung cancer, squamous medications
Category:PMDA approved drugs
Category:NMPA approved drugs
Nelarabine (Arranon)

==General information==
Class/mechanism: Purine analog, antimetabolite. Nelarabine is metabolized to the cytotoxic deoxyguanosine analog, 9-β-Darabinofuranosylguanine (ara-G), which is eventually converted to ara-GTP. ara-GTP is incorporated into DNA and leads to inhibition of DNA synthesis and cell death.Nelarabine (Arranon) package insertNelarabine (Arranon) package insert (locally hosted backup)
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is used==
* T-cell acute lymphoblastic leukemia-lymphoma (T-ALL)
==Patient drug information==
*Nelarabine (Arranon) package insert PDF pages 17-19
*Nelarabine (Arranon) patient drug information (Chemocare)Nelarabine (Arranon) patient drug information (Chemocare)
*Nelarabine (Arranon) patient drug information (UpToDate)Nelarabine (Arranon) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2005-10-28: Accelerated approval for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. (Based on Berg et al. 2005 and CALGB 19801)
**2019-07-31: Converted to regular approval for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. (Based on COG AALL0434)
==History of changes in EMA indication==
*2007-08-22: Initial authorization as Atriance
==History of changes in Health Canada indication==
*2007-09-22: Initial notice of compliance with conditions for use in the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
*2020-01-22: Conditions were met
==History of changes in PMDA indication==
*2007-10-19: Initial approval for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
==Also known as==
*Code name: 506U78
*Brand names: Arranon, Atriance
==References==
Category:Drugs
Category:Intravenous medications
Category:Neutral
Category:Antimetabolites
Category:Purine analogs
Category:T-cell acute lymphoblastic leukemia medications
Category:FDA approved in 2005
Category:EMA approved in 2007
Category:Health Canada approved in 2007
Category:PMDA approved in 2007
Netupitant and palonosetron (Akynzeo)

==General information==
Class/mechanism: Neurokinin 1 (NK1) antagonist and serotonin 5-HT3 antagonist combination pill. Netupitant is selective human substance P/neurokinin 1 (NK1) receptor antagonist. Netupitant blocks substance P activation of tachykinin family neurokinin 1 (NK1) receptors, which reduces the incidence of delayed emesis. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Palonosetron (Aloxi) prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.Netupitant and palonosetron (Akynzeo) package insert Netupitant and palonosetron (Akynzeo) package insert (locally hosted backup)Akynzeo manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
*Netupitant and palonosetron (Akynzeo) package insert
==History of changes in FDA indication==
*2014-10-10: FDA approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
==History of changes in EMA indication==
*2015-05-27: Initial authorization
==Also known as==
*Generic name: NEPA
*Brand name: Akynzeo
==References==
Category:Drugs
Category:Combination drugs
Category:Oral medications
Category:Emesis prevention
Category:Neurokinin 1 (NK1) antagonists
Category:Serotonin 5-HT3 antagonists
Category:FDA approved in 2014
Category:EMA approved in 2015
Neuroblastoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main neuroblastoma page for regimens that include active anticancer treatment.
=High-risk, consolidation after upfront induction=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Matthay et al. 1999	1991-1996 	Phase 3 (C)	Isotretinoin	Seems to have shorter EFS (primary endpoint)
No further treatment.
====Preceding treatment====
*Matthay et al. 1999: HDT with purged auto HSCT versus cisplatin, doxorubicin, etoposide consolidation
===References===
# Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999 Oct 14;341(16):1165-73. link to original article EuroPMC
Category:Neuroblastoma regimens
Category:Disease-specific pages
Category:Null regimens